Arthur Letellier1,2, Alison C Johnson3, Nicolas How Kit1,2, Jean-François Savigny4, Alain Batalla5, Jean-Jacques Parienti6,7, Nicolas Aide8,9. 1. Nuclear Medicine Department, Caen University Hospital, 14000, Caen, France. 2. Radiology Department, University Hospital, Caen, France. 3. Medical Oncology, François Baclesse Cancer Centre, Caen, France. 4. Nuclear Medicine Department, François Baclesse Cancer Centre, Caen, France. 5. Medical Physics, François Baclesse Cancer Centre, Caen, France. 6. Clinical Research Unit, University Hospital, Caen, France. 7. EA2656 (GRAM 2.0), Normandie University, Caen, France. 8. Nuclear Medicine Department, Caen University Hospital, 14000, Caen, France. aide-n@chu-caen.fr. 9. INSERM 1199 ANTICIPE, Normandie University, Caen, France. aide-n@chu-caen.fr.
Abstract
PURPOSE: The purpose of this study is to identify predictive factors on baseline [18F]NaF positron emission tomography (PET)/computed tomography (CT) of early response to radium-223 dichloride after 3 cycles of treatment in metastatic castration-resistant prostate cancer patients. PROCEDURES: Analysis of 152 metastases was performed in six consecutive patients who underwent [18F]NaF PET/CT at baseline and for early monitoring after 3 cycles of radium-223 dichloride. All metastases depicted on whole-body [18F]NaF PET/CT were contoured and CT (density in Hounsfield units, sclerotic, mixed, or lytic appearance) as well as [18F]NaF [maximum standardized uptake value (SUVmax), SUVmean, and lesion volume (V18F-NaF)] patterns were recorded. Tumor response was defined as percentage change in SUVmax and SUVmean between baseline and post-treatment PET. Bone lesions were defined as stable, responsive, or progressive, according to thresholds derived from a recent multicentre test-retest study in [18F]NaF PET/CT. Total [18F]NaF uptake in metastases, defined as MATV × SUVmean, was correlated to uptake of radium-223 on biodistribution scintigraphy performed 7 days after the first cycle of treatment. RESULTS: Among metastases, 116 involved the axial skeleton and 36 the appendicular skeleton. Lesions were sclerotic in 126 cases and mixed in 26 cases. No lytic lesion was depicted. ROC analysis showed that SUVmax and SUVmean were better predictors of lesion response than V18F-NaF and density on CT (P < 0.0001 and P = 0.001, respectively). SUVmax and SUVmean were predictors of individual tumor response in separate multivariate models (P = 0.01 and P = 0.02, respectively). CT pattern (mixed versus sclerotic) and lesion density were independent predictors only when assessing response with delta SUVmax (P = 0.002 and 0.007, respectively). A good correlation between total [18F]NaF uptake within metastases and their relative radium-223 uptake assessed by two observers 7 days after treatment (r = 0.72 and 0.77, P < 0.0001) was found. CONCLUSIONS: SUVmax and SUVmean on baseline [18F]NaF PET/CT are independent predictors of bone lesions' response to 3 cycles of radium-223 dichloride, supporting the use of NaF to select patients more likely to respond to treatment.
PURPOSE: The purpose of this study is to identify predictive factors on baseline [18F]NaF positron emission tomography (PET)/computed tomography (CT) of early response to radium-223 dichloride after 3 cycles of treatment in metastatic castration-resistant prostate cancerpatients. PROCEDURES: Analysis of 152 metastases was performed in six consecutive patients who underwent [18F]NaF PET/CT at baseline and for early monitoring after 3 cycles of radium-223 dichloride. All metastases depicted on whole-body [18F]NaF PET/CT were contoured and CT (density in Hounsfield units, sclerotic, mixed, or lytic appearance) as well as [18F]NaF [maximum standardized uptake value (SUVmax), SUVmean, and lesion volume (V18F-NaF)] patterns were recorded. Tumor response was defined as percentage change in SUVmax and SUVmean between baseline and post-treatment PET. Bone lesions were defined as stable, responsive, or progressive, according to thresholds derived from a recent multicentre test-retest study in [18F]NaF PET/CT. Total [18F]NaF uptake in metastases, defined as MATV × SUVmean, was correlated to uptake of radium-223 on biodistribution scintigraphy performed 7 days after the first cycle of treatment. RESULTS: Among metastases, 116 involved the axial skeleton and 36 the appendicular skeleton. Lesions were sclerotic in 126 cases and mixed in 26 cases. No lytic lesion was depicted. ROC analysis showed that SUVmax and SUVmean were better predictors of lesion response than V18F-NaF and density on CT (P < 0.0001 and P = 0.001, respectively). SUVmax and SUVmean were predictors of individual tumor response in separate multivariate models (P = 0.01 and P = 0.02, respectively). CT pattern (mixed versus sclerotic) and lesion density were independent predictors only when assessing response with delta SUVmax (P = 0.002 and 0.007, respectively). A good correlation between total [18F]NaF uptake within metastases and their relative radium-223 uptake assessed by two observers 7 days after treatment (r = 0.72 and 0.77, P < 0.0001) was found. CONCLUSIONS: SUVmax and SUVmean on baseline [18F]NaF PET/CT are independent predictors of bone lesions' response to 3 cycles of radium-223 dichloride, supporting the use of NaF to select patients more likely to respond to treatment.
Entities:
Keywords:
Bone metastases; PET/CT; Prostate cancer; Radium-223 dichloride; [18F]NaF
Authors: Aseem Anand; Michael J Morris; Reza Kaboteh; Lena Båth; May Sadik; Peter Gjertsson; Milan Lomsky; Lars Edenbrandt; David Minarik; Anders Bjartell Journal: J Nucl Med Date: 2015-08-27 Impact factor: 10.057
Authors: M Piert; T T Zittel; G A Becker; M Jahn; A Stahlschmidt; G Maier; H J Machulla; R Bares Journal: J Nucl Med Date: 2001-07 Impact factor: 10.057
Authors: M Beheshti; F M Mottaghy; F Paycha; F F F Behrendt; T Van den Wyngaert; I Fogelman; K Strobel; M Celli; S Fanti; F Giammarile; B Krause; W Langsteger Journal: Eur J Nucl Med Mol Imaging Date: 2015-07-23 Impact factor: 9.236
Authors: Eric M Rohren; Elba C Etchebehere; John C Araujo; Brian P Hobbs; Nancy M Swanston; Michael Everding; Tracy Moody; Homer A Macapinlac Journal: J Nucl Med Date: 2015-07-01 Impact factor: 10.057
Authors: Robert F Hobbs; Hong Song; Christopher J Watchman; Wesley E Bolch; Anne-Kirsti Aksnes; Thomas Ramdahl; Glenn D Flux; George Sgouros Journal: Phys Med Biol Date: 2012-05-01 Impact factor: 3.609
Authors: S Nilsson; P Cislo; O Sartor; N J Vogelzang; R E Coleman; J M O'Sullivan; J Reuning-Scherer; M Shan; L Zhan; C Parker Journal: Ann Oncol Date: 2016-02-23 Impact factor: 32.976
Authors: Jyoti Roy; Margaret E White; Falguni Basuli; Ana Christina L Opina; Karen Wong; Morgan Riba; Anita T Ton; Xiang Zhang; Keith H Jansson; Elijah Edmondson; Donna Butcher; Frank I Lin; Peter L Choyke; Kathleen Kelly; Elaine M Jagoda Journal: Mol Imaging Biol Date: 2021-04-23 Impact factor: 3.488
Authors: Tim E Phelps; Jyoti Roy; Michael V Green; Jurgen Seidel; Kwamena E Baidoo; Stephen Adler; Elijah F Edmondson; Donna Butcher; Jennifer L Matta; Anita T Ton; Karen Wong; Shan Huang; Ling Ren; Amy K LeBlanc; Peter L Choyke; Elaine M Jagoda Journal: Cancer Biother Radiopharm Date: 2021-02-25 Impact factor: 3.099
Authors: Nadia Benabdallah; William Scheve; Nicholas Dunn; Delynn Silvestros; Paul Schelker; Diane Abou; Uday Jammalamadaka; Richard Laforest; Zekun Li; Jonathan Liu; David H Ballard; Nichole M Maughan; Hiram Gay; Brian C Baumann; Robert F Hobbs; Buck Rogers; Amir Iravani; Abhinav K Jha; Farrokh Dehdashti; Daniel L J Thorek Journal: Theranostics Date: 2021-09-27 Impact factor: 11.556
Authors: Matteo Bauckneht; Sara Elena Rebuzzi; Marta Ponzano; Roberto Borea; Alessio Signori; Viviana Frantellizzi; Elisa Lodi Rizzini; Manlio Mascia; Valentina Lavelli; Alberto Miceli; Maria Silvia De Feo; Antonio Rosario Pisani; Susanna Nuvoli; Vincenzo Tripoli; Alessio Giuseppe Morganti; Paolo Mammucci; Salvatore Caponnetto; Guglielmo Mantica; Angelo Domenico Di Nicola; Carlo Villano; Luca Cindolo; Silvia Morbelli; Gianmario Sambuceti; Stefano Fanti; Renato Patrizio Costa; Angela Spanu; Giuseppe Rubini; Fabio Monari; Giuseppe De Vincentis; Giuseppe Fornarini Journal: Cancers (Basel) Date: 2022-03-29 Impact factor: 6.639